Add BrightSurf on Google Email

Identified the genetic landscape of myelodysplastic/myeloproliferative neoplasms

A study published in the Journal Blood reveals the molecular landscape of myelodysplastic/myeloproliferative neoplasms (MDS/MPN), a group of rare malignancies with overlapping features. The researchers identified genotype-phenotype associations and potential diagnostic molecular markers that can improve diagnosis and risk stratificatio...

The Lancet Haematology: First global estimates suggest around 100 million more blood units are needed in countries with low supplies each year

The global demand for blood transfusions exceeds the available supply by 30 million units annually, with the largest shortages found in lower-income countries. The estimated shortfall varies sharply between countries, with some requiring up to 75 times more blood than their supply can provide.

SourceThe Lancet·JournalThe Lancet Haematology·DateOct 17, 2019

Timing of end-of-life discussions for patients with blood cancers

A majority of hematologic oncologists report that end-of-life discussions happen too late, with most discussions occurring when death was clearly imminent. The delay may be attributed to the curative potential of many advanced hematologic cancers, leading to a lack of clear distinction between curative and palliative care phases.

SourceJAMA Network·JournalJAMA Internal Medicine·DateDec 21, 2015

McMaster hematologist identifies different limb loss syndromes

A McMaster University hematologist has identified various limb loss syndromes, including symmetric peripheral gangrene and venous limb gangrene, which can be caused by septic shock, cancer, and blood clotting disorders. The treatment for these conditions involves the use of blood thinners and replacement of protective factors.

SourceMcMaster University·JournalNew England Journal of Medicine·DateAug 12, 2015

American Society of Hematology releases list of commonly used tests and treatments to question as part of Choosing Wisely campaign

The American Society of Hematology has released a list of common hematology tests, treatments, and procedures that are not always necessary. The list highlights five tests or procedures to question, including limiting surveillance CT scans in asymptomatic patients following curative-intent treatment for aggressive lymphoma.